Hey, this is an English text. I want you to translate it into the Tunisian dialect. Please follow these steps:
1. Translate step by step and highlight differences between Tunisian dialect and Modern Standard Arabic.
2. Highlight sections you are confident translating into the Tunisian dialect.
Translate this text into the Tunisian dialect, focusing on capturing the essence of the language nuances:

INTRODUCTION {#s1} ============ Alveolar rhabdomyosarcoma (ARMS) is a highly aggressive soft tissue sarcoma affecting children and adolescent age groups. At the genomic level it can be associated with translocations involving t(2;13) or t(1;13) resulting in fusion transcripts of PAX3-FKHR (FOXO1) and PAX7-FKHR (FOXO1) genes and corresponding proteins, reportedly accounting for 55% and 22% of ARMS, respectively in one study \[[@R1]\]. Moreover, in this same study the PAX3-FKHR group demonstrated an estimated 4-year overall survival of only 8% and with metastatic disease, a significant increased risk of failure and death. The biology of ARMS has recently been summarized to include blocks in differentiation and promotion of proliferation in the context of genomic aberrations and specifically, has incorporated the insulin-like growth factor (IGF), c-Met, GSK3-β, transforming growth factor (TGF)-beta/Gli2, YY1, and enhancer of Zeste homolog 2 (EZH2) pathways \[[@R2]--[@R17]\]. In short, by neutralizing the biological influence of the fusion transcript and protein, PAX3-FKHR (FOXO1) and targeting the pathways that impose both a block in differentiation and facilitate proliferation, we should be able to convert this aggressive and lethal form of ARMS to a more benign and indolent state and prevent recurrent disease. The purpose of this report is threefold: 1. to present genomic and morphoproteomic findings in a patient with PAX3-FKHR (FOXO1) ARMS that help to further define the biology of this subtype; 2. to show, in a xenograft model, confirmation of therapies that could target its genomic and proteomic biology and the block in differentiation and lead to tumoral regression and/or tumoral growth inhibition; and 3. to propose a clinically scientific treatment regimen that could be used in both an initial and maintenance mode to target the biology of PAX3-FKHR (FOXO1) subtype of ARMS, remove the block in differentiation and minimize the risk of recurrent disease. RESULTS {#s2} ======= Patient clinical course and treatment history {#s2_1} --------------------------------------------- A 10 year-old male had originally presented with alveolar rhabdomyosarcoma of the left hand with a positive axillary lymph node for which he underwent chemoradiation therapy (x15 months). He then recurred at age 12 with an abdominal mass in the soft tissue of the retroperitoneal region and in the subcutaneous region of the back for which he received vinorelbine, cyclophosphamide and temsirolimus, with a reported 70% tumor reduction. Unfortunately, the patient\'s ARMS subsequently recurred again, this time with new testicular and retroperitoneal lesions and brain metastasis for which he was treated with temozolomide and irinotecan, and then metformin and vorinostat approximately one month prior to the biopsy of the right lower quadrant mass. He died at age 14 with metastasis to the brain and leptomeningeal sarcomatosis. An autopsy also revealed extensive metastatic disease in the organs of the abdominal cavity, the retroperitoneum, diaphragm and rib cage, but with no metastatic nodules in the lung parenchyma. Molecular analyses {#s2_2} ------------------ Fluorescent *in situ* hybridization (FISH) analysis was performed on a biopsy from the retroperitoneal biopsy by an outside hospital and confirmed the presence of *FKHR (FOXO1)* gene rearrangement. A subsequent independent genomic report from a